YAKULT HONSHA CO.,LTD.
2267・Prime Market・Foods
Business
Yakult Honsha Co., Ltd. was founded in 1935 and established as its current corporate entity in 1955, and is a global leader in lactic acid bacteria beverages. Centered on its proprietary "Lactobacillus casei strain Shirota," the company's core product is the "Yakult" series of fermented milk drinks, which it manufactures and sells across 39 countries and regions. Domestically, it operates a dual-channel model of home delivery and retail sales through 106 Yakult sales companies nationwide, while overseas it maintains 26 business offices across the Americas, Asia, Oceania, and Europe. The company also engages in cosmetics, pharmaceuticals, and professional baseball operations, but its beverage and food manufacturing and sales business accounts for approximately 94% of total revenue. For FY2026 (ending March 2026), consolidated revenue is ¥486,425 million, with total assets of ¥912,578 million.
Business Model
By combining the door-to-door delivery system operated by Yakult Ladies with storefront retail channels, the company appeals directly to consumers regarding the health value of "Lactobacillus casei strain Shirota" and encourages continued consumption. In Japan, the company works through an indirect sales structure in which 106 sales companies purchase and sell products, while overseas, local subsidiaries operate manufacturing and sales in an integrated manner. The accumulation of scientific evidence, backed by R&D expenditure of ¥9,733 million (FY2026, ending March 2026), supports product differentiation and price premiums, with high-value-added products such as "Yakult1000" and "Y1000" contributing to improved profitability.
Company Strengths
The direct sales organization comprising 106 Yakult sales companies nationwide and Yakult Ladies constitutes a proprietary distribution infrastructure that is difficult for competitors to replicate in the short term. The dual-channel approach of home delivery and retail sales promotes continued consumption, supporting the penetration of high-value-added products such as "Yakult 1000". This distribution network is also utilized for door-to-door cosmetics sales, serving as a cross-business revenue foundation.
Starting with entry into Taiwan in 1964, the company now operates in 39 countries and regions, with the overseas sales ratio reaching 49.5% in FY2026 (ending March 2026). It maintains local manufacturing bases across the Americas, Asia, Oceania, and Europe, with the Americas segment achieving a high operating margin of 26.1%. Regional diversification reduces dependency risk on specific markets while expanding earnings contribution from growth markets.
Research findings on "Lactobacillus casei strain Shirota (L. paracasei strain Shirota)" — including suppression of upper respiratory tract infections, reduced incidence of anemia in the elderly, and improvement of intestinal environment — continue to be published in international academic journals. R&D expenses for FY2026 (ending March 2026) totaled ¥9,733 million. The "Yakult" brand was certified by Guinness World Records in October 2024 as the "largest lactic acid bacteria beverage/probiotic drink brand", with scientific credibility and brand recognition forming a competitive advantage.
ENVALITH's Perspective
Performance Trend
Revenue peaked at ¥503,079 million in FY2024 (ended March 2024), then declined for three consecutive periods: ¥499,683 million in FY2025 (ended March 2025) (down 0.7% year on year) and ¥486,425 million in FY2026 (ending March 2026) (down 2.7% year on year). Operating profit fell approximately 32% over three periods, from ¥66,068 million in FY2023 (ended March 2023) to ¥45,185 million in FY2026 (ending March 2026), with the operating margin declining from 11.1% (FY2025, ended March 2025) to 9.3% (FY2026, ending March 2026). In addition to intensifying domestic competition and changes in consumer behavior driven by price inflation, soaring raw material costs, logistics costs, and fuel costs squeezed profitability. External factors such as foreign exchange fluctuations (a decline in interest income received: from ¥13,076 million in the prior period to ¥9,254 million in the current period) also contributed to the decline in ordinary profit (from ¥75,860 million to ¥61,084 million). For FY2027 (ending March 2027), revenue is forecast at ¥527,000 million (up 8.3% year on year), but operating profit is expected to decline further to ¥44,000 million (down 2.6% year on year).
Growth Strategy
Aiming for net sales of ¥700,000 million by FY2030 through the twin pillars of overseas "deepening and expansion" and strengthening domestic high-value-added products.
Expanding the product portfolio through the launch of foods with function claims such as "Y1000 Sugar-Free" and the rollout of the "Soymilk Power" series in the home-delivery channel. Continuing evidence-based value messaging around "Lactobacillus casei strain Shirota" across both home-delivery and retail channels, aiming for a sales recovery amid intensifying competition and rising prices. A continued challenging environment is anticipated for the domestic business in FY2027 (ending March 2027).
Securing future production capacity through increasing the number of retail outlets carrying products in the U.S. and constructing a second plant (capital expenditure of ¥45,993 million in FY2026, ending March 2026). Continuing to stimulate demand through the launch of new flavors in Brazil and Mexico. The U.S. business continued to perform well in FY2026 (ending March 2026), and expanded profit contribution is expected once investments are recouped.
Aiming to expand results through the expansion of the home-delivery organization in Vietnam, flavor rollout in China, and new product launches in Indonesia. In China, management resources have already been streamlined through consolidation of production sites via the closure of the first Guangzhou plant. Segment profit for FY2026 (ending March 2026) improved to ¥12,611 million (from ¥10,794 million in the prior period), confirming a positive trajectory in profitability improvement.
Promoting the launch of Europe-specific proprietary products such as "Yakult Vitals," operational efficiency through the absorption-type merger of an Austrian subsidiary, and strengthened local responsiveness via the "Yakult European R&D Center B.V." (established September 2025). Segment profit for FY2026 (ending March 2026) remained in the red at ¥-91 million, with turning profitable the most immediate challenge.
Continuing shareholder returns combining a progressive dividend policy (forecast of ¥72 per share for FY2027, ending March 2027) with share buybacks targeting a total payout ratio of around 70%. Having set a policy of cumulative share buybacks of ¥100 billion or more by FY2030, the company resolved in May 2026 to conduct buybacks of up to ¥55 billion (with all repurchased shares to be cancelled). The company aims to achieve the cumulative target amount within FY2026.
Last updated: July 19, 2026